SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

Search

Eurofins Scientific SE

Gesloten

64.9 3.84

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

62.48

Max

65.34

Belangrijke statistieken

By Trading Economics

Inkomsten

105M

228M

Verkoop

1.9B

3.7B

K/W

Sectorgemiddelde

23.828

69.273

Dividendrendement

1.18

Winstmarge

6.2

Werknemers

65,694

EBITDA

285M

693M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+17.08% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.18%

3.43%

Volgende Winsten

1 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.8B

11B

Vorige openingsprijs

61.06

Vorige sluitingsprijs

64.9

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Eurofins Scientific SE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Nike, RH, NCino

31 mrt 2026, 22:35 UTC

Winsten

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisities, Fusies, Overnames

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mrt 2026, 23:50 UTC

Acquisities, Fusies, Overnames

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mrt 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mrt 2026, 23:21 UTC

Winsten

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mrt 2026, 23:14 UTC

Marktinformatie
Winsten

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mrt 2026, 23:12 UTC

Marktinformatie

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss Widens >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mrt 2026, 21:46 UTC

Acquisities, Fusies, Overnames

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mrt 2026, 21:36 UTC

Marktinformatie

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 21:33 UTC

Winsten

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mrt 2026, 21:32 UTC

Winsten

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mrt 2026, 21:28 UTC

Winsten

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mrt 2026, 21:26 UTC

Winsten

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mrt 2026, 21:25 UTC

Winsten

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mrt 2026, 21:24 UTC

Marktinformatie
Winsten

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mrt 2026, 21:22 UTC

Winsten

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mrt 2026, 21:22 UTC

Winsten

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mrt 2026, 21:21 UTC

Winsten

Nike's Digital Channel Still Too Promotional, CFO Says

31 mrt 2026, 21:20 UTC

Winsten

Nike CEO: Converse Remains Important to Portfolio

Peer Vergelijking

Prijswijziging

Eurofins Scientific SE Prognose

Koersdoel

By TipRanks

17.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 73.43 EUR  17.08%

Hoogste 81 EUR

Laagste 64 EUR

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eurofins Scientific SE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

54.22 / 56.82Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
help-icon Live chat